

**ICER Analytics<sup>™</sup>** is a new cloud-based platform that facilitates the use of ICER's evidence reports and underlying analyses by decision-makers as they:

- Develop medical policy
- Establish drug pricing
- Negotiate drug reimbursement

Available on a subscription basis, the platform provides users with a suite of tools that streamline interpretation of ICER's analyses – directly from the source – all designed to support integration into users' own pricing and reimbursement work. ICER Analytics subscribers have access to ICER's price benchmarks, cost-effectiveness results, comparative clinical effectiveness judgments, policy recommendations, and economic models within two primary tools.

## ICER Evidence Compendium<sup>™</sup>

The Evidence Compendium is a rapidly searchable and sortable summary of results from ICER's library of evidence reports, featuring:



Clinical effectiveness ratings



Pricing benchmarks for each drug and indication



Exclusive curated videos explaining the key takeaways from each of ICER's reports



Ability for users to enter the price they are charging or paying – desired or actual – and compare to existing benchmarks

# ICER Interactive Modeler™

The Interactive Modeler is a modifiable rendering of the actual ICER analytic model used to produce a specific evidence report. Users have the unique ability to:



Analyze key aspects of individual economic models produced for ICER Evidence Reports



Vary parameter inputs to the model based on a specific patient sub-population or unique cost structure



Publish alternative pricing benchmarks based on updated assumptions and new evidence to users of the Evidence Compendium



*ICER* Analytics is relevant for stakeholders across all sectors of health care: payers, pharmaceutical companies, patient advocates, employers, and others.

# **ADDITIONAL FEATURES OF ICER ANALYTICS**

### **Payers and Employers**

- More accurately understand the cost-effectiveness and budget impact of health care interventions specific to your patient population
- Evaluate negotiated agreements with pharmaceutical manufacturers and hospital systems or other providers

### **Pharmaceutical Companies**

- Assemble more fulsome dossiers to support products in conversations with payers by using new and emerging evidence in the ICER models
- Perform phase II-III analyses of emerging agents on the ICER model template to explore potential pricing levels

#### Patient Advocates

- View the patient perspectives that will influence payers and other policymakers
- Evaluate the impact of differential patient values on cost-effectiveness

#### All Stakeholders

- Review voting records and key stakeholder commentary from ICER's public meetings
- Compare results between different treatments in a therapeutic class

To request your free trial, please fill out the ICER Analytics interest form

For questions, please contact: <u>analytics@icer.org</u>